EUVIMEDEUVIMED entdecken
Crossref

Metabolic dysfunction-associated steatotic liver disease versus depression and anxiety disorders — clinical implications

Karolina Molenda, Agnieszka Kuduk, Szymon Muszynski, Agata Horecka-Lewitowicz, Lukasz Piwonski, Iwona Gorczyca-Glowacka

Journal of Sexual and Mental Health · 2025

DOI: 10.5603/jsmh.106887 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Sexual and Mental Health, 2025. Verfasst von Karolina Molenda und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common condition, alsoin the population of patients with psychiatric disorders.

Aim

This narrative research investigated the complex association of depression and anxiety disorderswith MASLD and identified the common underlying mechanisms of the conditions.Material and methods: A systematic review of the literature on depression, anxiety disorders, and MASLDwas conducted. Relevant articles were identified using PubMed and Google Scholar, with a primary focuson recent publications. This article expands on the findings of the selected studies. The inclusion criteriaprioritized peer-reviewed studies published in the last eight years and those with clinically relevant outcomes.Results and discussion: Patients with depression and anxiety disorders often lead sedentary lifestyles,are physically inactive, and have unhealthy eating habits, which may contribute to obesity, diabetes,hypertension, and hypercholesterolemia. These conditions are components of metabolic syndrome, whichis directly linked to MASLD. Abnormal gut microbiota is also significantly associated with the condition.Chronic stress, sleep disturbances, and neuroendocrine dysregulation may further exacerbate metabolicimbalance. Special attention should be given to the appropriate selection of psychiatric medications inthis patient group in consideration of the metabolic profile of each drug.

Conclusions

In clinical practice, careful management is essential for psychiatric patients with a well-establisheddiagnosis of MASLD. Their management should consider the potential risks of weight gain and increasedappetite. Multidisciplinary collaboration between psychiatrists, hepatologists, and dietitians may improvetreatment outcomes. Further research is needed to explore the pathophysiological mechanisms underlyingthe observed associations and the potential consequences of MASLD in depression and anxiety disorders.

Zitieren

APA

Molenda, K., Kuduk, A., Muszynski, S., Horecka-Lewitowicz, A., Piwonski, L., & Gorczyca-Glowacka, I. (2025). Metabolic dysfunction-associated steatotic liver disease versus depression and anxiety disorders — clinical implications. Journal of Sexual and Mental Health. https://doi.org/10.5603/jsmh.106887

Vancouver

Molenda K, Kuduk A, Muszynski S, Horecka-Lewitowicz A, Piwonski L, Gorczyca-Glowacka I. Metabolic dysfunction-associated steatotic liver disease versus depression and anxiety disorders — clinical implications. Journal of Sexual and Mental Health. 2025. doi:10.5603/jsmh.106887

BibTeX
@article{Molenda2025,
  author = {Molenda, Karolina and Kuduk, Agnieszka and Muszynski, Szymon and Horecka-Lewitowicz, Agata and Piwonski, Lukasz and Gorczyca-Glowacka, Iwona},
  title = {Metabolic dysfunction-associated steatotic liver disease versus depression and anxiety disorders — clinical implications},
  journal = {Journal of Sexual and Mental Health},
  year = {2025},
  doi = {10.5603/jsmh.106887}
}
Kostenlos starten →